Quantitative high-performance liquid chromatographic determination of acrolein in plasma after derivatization with Luminarin ® 3

A rapid, sensitive and specific high-performance liquid chromatographic method for the quantification of acrolein ( 1), one of the toxic metabolites of oxazaphosphorine alkylating agents (cyclophosphamide and ifosfamide) was developed. Condensation of acrolein with Luminarin ® 3 afforded a fluoresce...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chromatography. B, Biomedical sciences and applications Biomedical sciences and applications, 2000-03, Vol.739 (2), p.239-246
Main Authors: Paci, A, Rieutord, A, Guillaume, D, Traoré, F, Ropenga, J, Husson, H.-P, Brion, F
Format: Article
Language:English
Subjects:
Acrolein
Acrolein - blood
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Chromatography, High Pressure Liquid - methods
Cyclophosphamide
Fluorescent Dyes - chemistry
Humans
Ifosfamide
Luminarin
Magnetic Resonance Spectroscopy
Mass Spectrometry
Medical sciences
Pharmacology. Drug treatments
Quinolizines - chemistry
Reproducibility of Results
Sensitivity and Specificity
Spectrometry, Fluorescence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A rapid, sensitive and specific high-performance liquid chromatographic method for the quantification of acrolein ( 1), one of the toxic metabolites of oxazaphosphorine alkylating agents (cyclophosphamide and ifosfamide) was developed. Condensation of acrolein with Luminarin ® 3 afforded a fluorescent derivative that could be specifically detected and quantified. Chromatographic conditions involved a C 18 RP column Uptisphere and a gradient elution system to optimize resolution and time analysis. The method showed high sensitivity with a limit of detection of 100 pmol/ml and a limit of quantification of 300 pmol/ml. This technique is particularly suitable for pharmacokinetic studies on plasma of oxazaphosphorine-receiving patients.
ISSN:0378-4347
1387-2273
DOI:10.1016/S0378-4347(99)00485-5